HRP20210965T1 - Derivati pirazolilaminobenzimidazola kao jak inhibitori - Google Patents
Derivati pirazolilaminobenzimidazola kao jak inhibitori Download PDFInfo
- Publication number
- HRP20210965T1 HRP20210965T1 HRP20210965TT HRP20210965T HRP20210965T1 HR P20210965 T1 HRP20210965 T1 HR P20210965T1 HR P20210965T T HRP20210965T T HR P20210965TT HR P20210965 T HRP20210965 T HR P20210965T HR P20210965 T1 HRP20210965 T1 HR P20210965T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- pharmaceutically acceptable
- image
- acceptable salt
- amino
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- DHHDAEXWDQTBIJ-UHFFFAOYSA-N n-(1h-pyrazol-5-yl)-1h-benzimidazol-2-amine Chemical class N=1C2=CC=CC=C2NC=1NC1=CC=NN1 DHHDAEXWDQTBIJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 229910016523 CuKa Inorganic materials 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (19)
1. Spoj formule, ili njegova farmaceutski prihvatljiva sol
[image]
gdje R je izabran između: H, -C1-3 alkil, -CH2CH(OH)CH3, -C2-3 alkil-O-CH3,
[image]
R1 je izabran između: H, -CH3, i -OCH3;
R2 je -CHF2 ili -CF3; i
R3 je H ili -CH3;
uz uvjet da kada R2 je -CF3 i R3 je H, ili R ili R1 mogu biti -CH3, ali ne oba.
2. Spoj prema zahtjevu 1 formule, ili njegova farmaceutski prihvatljiva sol,
[image]
gdje:
R je izabran između: H, -C1-3 alkil, -CH2CH(OH)CH3, -C2-3 alkil-O-CH3,
[image]
i
[image]
R1 je izabran između: H, -CH3, i -OCH3;
R2 je -CHF2 ili -CF3; i
R3 je H ili -CH3;
uz uvjet da kad R2 je -CF3, i R3 je H, ili R ili R1 mogu biti -CH3, ali ne oba.
3. Spoj prema zahtjevu 1 ili 2 gdje R je izabran između: -CH3, -CH2CH3, i
[image]
ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema bilo kojem od zahtjeva 1 do 3 gdje R je -CH3, ili -CH2CH3, ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od zahtjeva 1 do 3 gdje R je
[image]
ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema bilo kojem od zahtjeva 1 do 5 gdje R2 je -CF3, ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od zahtjeva 1 do 6 gdje R3 je -CH3, ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od zahtjeva 1 do 4 koje je
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema bilo kojem od zahtjeva 1 do 4 koje je
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema zahtjevu 1 ili 2 koje je
[image]
ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema bilo kojem od zahtjeva 1 do 3, ili 5 koje je
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema bilo kojem od zahtjeva 1 do 3, ili 5 koje je (2R)-1,1,1-trifluoro-3-({cis-4-[(1-metil-4-{[1-(piridin-2-il)-1H-pirazol-3-il]amino}-1H-benzimidazol-6-il)oksi]cikloheksil}amino)propan-2-ol2-hidroksipropan-1,2,3-trikarboksilat hidrat.
13. Spoj prema bilo kojem od zahtjeva 1 do 3, ili 5 koje je (2R)-1,1,1-trifluoro-3-({cis-4-[(1-metil-4-{[1-(piridin-2-il)-1H-pirazol-3-il]amino}-1H-benzimidazol-6-il)oksi]cikloheksil}amino)propan-2-ol u kristalnom obliku karakteriziranom spektrom difrakcije X-zraka na prahu dobivenom sa CuKa izvorom (λ=1.54060 Å), koji ima signal na 20.5 u kombinaciji sa jednim ili više signala izabranih iz grupe koju čine 15.5, 18.1, 18.3, 18.5, 22.9 i 23.6; sa odstupanjem difrakcijskih uglova od 0.2 stupnjeva.
14. Spoj prema bilo kojem od zahtjeva 1 do 3, ili 5 koje je (2R)-1,1,1-trifluoro-3-({cis-4-[(1-metil-4-{[1-(piridin-2-il)-1H-pirazol-3-il]amino}-1H-benzimidazol-6-il)oksi]cikloheksil}amino)propan-2-ol 2-hidroksipropan-1,2,3-trikarboksilat hidrat u kristalnom obliku karakteriziranom spektrom difrakcije X-zraka na prahu dobivenom pomoću CuKa izvora (λ=1.54060 Å), koji ima signal na 17.9 u kombinaciji sa jednim ili više signala izabranih iz grupe koju čine 26.1, 26.6 i 22.7; sa odstupanjem difrakcijskih uglova od 0.2 stupnjeva.
15. Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1 do 14 i farmaceutski prihvatljiv nositelj, razblaživač ili ekscipijent.
16. Farmaceutski sastav prema zahtjevu 15 koji sadrži više od 80% m/m spoja koji je (2R)-1,1,1-trifluoro-3-({cis-4-[(1-metil-4-{[1-(piridin-2-il)-1H-pirazol-3-il]amino}-1H-benzimidazol-6-il)oksi]cikloheksil}amino)propan-2-ol2-hidroksipropan-1,2,3-trikarboksilat hidrat u kristalnom obliku.
17. Farmaceutski sastav prema zahtjevu 15 koja sadrži više od 90 % m/m spoja koji je (2R)-1,1,1-trifluoro-3-({cis-4-[(1-metil-4-{[1-(piridin-2-il)-1H-pirazol-3-il]amino}-1H-benzimidazol-6-il)oksi]cikloheksil}amino)propan-2-ol2-hidroksipropan-1,2,3-trikarboksilat hidrat u kristalnom obliku.
18. Spoj prema bilo kojem od zahtjeva 1 do 14 za upotrebu u liječenju.
19. Spoj prema bilo kojem od zahtjeva 1 do 14 za upotrebu u liječenju artritisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362208P | 2016-07-14 | 2016-07-14 | |
| EP17740885.3A EP3484875B1 (en) | 2016-07-14 | 2017-07-10 | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
| PCT/US2017/041388 WO2018013486A1 (en) | 2016-07-14 | 2017-07-10 | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210965T1 true HRP20210965T1 (hr) | 2021-09-17 |
Family
ID=59366549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210965TT HRP20210965T1 (hr) | 2016-07-14 | 2021-06-17 | Derivati pirazolilaminobenzimidazola kao jak inhibitori |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10323019B2 (hr) |
| EP (1) | EP3484875B1 (hr) |
| JP (1) | JP6712331B2 (hr) |
| KR (1) | KR102225840B1 (hr) |
| CN (1) | CN109476643B (hr) |
| AU (1) | AU2017296026B2 (hr) |
| BR (1) | BR112018075086B1 (hr) |
| CA (1) | CA3030697C (hr) |
| CY (1) | CY1124308T1 (hr) |
| DK (1) | DK3484875T3 (hr) |
| EA (1) | EA038129B1 (hr) |
| ES (1) | ES2877198T3 (hr) |
| HR (1) | HRP20210965T1 (hr) |
| HU (1) | HUE054912T2 (hr) |
| LT (1) | LT3484875T (hr) |
| MX (1) | MX2019000542A (hr) |
| NZ (1) | NZ748942A (hr) |
| PL (1) | PL3484875T3 (hr) |
| PT (1) | PT3484875T (hr) |
| RS (1) | RS61991B1 (hr) |
| SI (1) | SI3484875T1 (hr) |
| WO (1) | WO2018013486A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230141115A (ko) | 2022-03-31 | 2023-10-10 | 한림대학교 산학협력단 | 신규한 2-아릴-1H-벤조[d]이미다졸 유도체, 이의 제조 방법 및 이의 항암제로서의 용도 |
| KR102582097B1 (ko) | 2022-12-28 | 2023-09-25 | (주)메디언스 | 야누스키나아제 표적 억제제 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用 |
| US8445676B2 (en) * | 2008-10-08 | 2013-05-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| CN102712640A (zh) * | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
| AR083933A1 (es) * | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| WO2013040863A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016065138A1 (en) * | 2014-10-22 | 2016-04-28 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
-
2017
- 2017-07-10 NZ NZ748942A patent/NZ748942A/en unknown
- 2017-07-10 WO PCT/US2017/041388 patent/WO2018013486A1/en active Application Filing
- 2017-07-10 BR BR112018075086-7A patent/BR112018075086B1/pt active IP Right Grant
- 2017-07-10 HU HUE17740885A patent/HUE054912T2/hu unknown
- 2017-07-10 JP JP2018567741A patent/JP6712331B2/ja active Active
- 2017-07-10 CA CA3030697A patent/CA3030697C/en active Active
- 2017-07-10 SI SI201730827T patent/SI3484875T1/sl unknown
- 2017-07-10 DK DK17740885.3T patent/DK3484875T3/da active
- 2017-07-10 PL PL17740885T patent/PL3484875T3/pl unknown
- 2017-07-10 PT PT177408853T patent/PT3484875T/pt unknown
- 2017-07-10 ES ES17740885T patent/ES2877198T3/es active Active
- 2017-07-10 KR KR1020197000782A patent/KR102225840B1/ko active IP Right Grant
- 2017-07-10 AU AU2017296026A patent/AU2017296026B2/en active Active
- 2017-07-10 RS RS20210756A patent/RS61991B1/sr unknown
- 2017-07-10 EA EA201892698A patent/EA038129B1/ru not_active IP Right Cessation
- 2017-07-10 EP EP17740885.3A patent/EP3484875B1/en active Active
- 2017-07-10 CN CN201780043606.5A patent/CN109476643B/zh active Active
- 2017-07-10 MX MX2019000542A patent/MX2019000542A/es unknown
- 2017-07-10 LT LTEP17740885.3T patent/LT3484875T/lt unknown
- 2017-07-10 US US15/775,990 patent/US10323019B2/en active Active
-
2019
- 2019-02-12 US US16/273,706 patent/US10344018B2/en active Active
-
2021
- 2021-06-17 HR HRP20210965TT patent/HRP20210965T1/hr unknown
- 2021-07-02 CY CY20211100588T patent/CY1124308T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3484875T1 (sl) | 2021-08-31 |
| MX2019000542A (es) | 2019-07-04 |
| EP3484875B1 (en) | 2021-04-07 |
| CN109476643B (zh) | 2021-06-08 |
| JP6712331B2 (ja) | 2020-06-17 |
| WO2018013486A1 (en) | 2018-01-18 |
| HUE054912T2 (hu) | 2021-10-28 |
| EP3484875A1 (en) | 2019-05-22 |
| PT3484875T (pt) | 2021-07-05 |
| CA3030697A1 (en) | 2018-01-18 |
| KR102225840B1 (ko) | 2021-03-11 |
| US10344018B2 (en) | 2019-07-09 |
| BR112018075086A2 (pt) | 2019-03-12 |
| DK3484875T3 (da) | 2021-06-28 |
| ES2877198T3 (es) | 2021-11-16 |
| RS61991B1 (sr) | 2021-07-30 |
| JP2019525908A (ja) | 2019-09-12 |
| EA201892698A1 (ru) | 2019-06-28 |
| NZ748942A (en) | 2020-08-28 |
| KR20190015561A (ko) | 2019-02-13 |
| AU2017296026A1 (en) | 2018-12-20 |
| CN109476643A (zh) | 2019-03-15 |
| AU2017296026B2 (en) | 2019-11-21 |
| CY1124308T1 (el) | 2022-07-22 |
| US20190177300A1 (en) | 2019-06-13 |
| US10323019B2 (en) | 2019-06-18 |
| CA3030697C (en) | 2021-02-23 |
| LT3484875T (lt) | 2021-07-26 |
| PL3484875T3 (pl) | 2021-11-02 |
| US20180325873A1 (en) | 2018-11-15 |
| BR112018075086B1 (pt) | 2024-02-27 |
| EA038129B1 (ru) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210965T1 (hr) | Derivati pirazolilaminobenzimidazola kao jak inhibitori | |
| HRP20211043T1 (hr) | Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| HRP20170873T1 (hr) | Monociklički derivat piridina | |
| HRP20200274T1 (hr) | Terapeutski aktivni spojevi i postupci njihove uporabe | |
| IL264709B2 (en) | Pharmaceutical preparations containing a modified polycyclic pyridone derivative and a hemane prodrug | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| MY152955A (en) | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| CA2875877C (en) | Syk inhibitors | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| NO20081128L (no) | 4-fenyl-6-substituerte-pyrimidin-2-karbonitrilderivater | |
| EA201590023A1 (ru) | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| AR114420A1 (es) | Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| EA201590021A1 (ru) | Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| EA201890361A1 (ru) | Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| FI3722291T3 (fi) | Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса |